Alpine Immune Sciences price target raised to $17 from $11 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Alpine Immune Sciences to $17 from $11 and keeps a Buy rating on the shares post the Q2 report. The analyst says the RUBY-3 and RUBY-4 studies later this year should help drive pivotal plans for specific indications as well as potentially define a path toward accelerated approval.